downsides of retatrutide Lilly's shows 28% weight loss, but increased side effects Retatrutide UK 2026: Phase 3

JAMA 324 , 879 (2020)

Monitor for localized metabolic dullness, nausea, or altered gastric emptying, which are common secondary responses during the maintenance phase

Phase 2 trials showed up to 24% body weight reduction

This reflects the broader GLP-1 microbiome connection, in which GLP-1 regulation is tightly linked to gut barrier integrity, microbial diversity, and mucin-degrading bacteria such as Akkermansia muciniphila

Ethics declarations Competing interests Through M.H.H.K., the VU University Medical Center has received research grants from AstraZeneca, Boehringer Ingelheim, Novo Nordisk and Sanofi

The comparison between GLP-1RA and SGLT-2 inhibitors shows no difference in their risk for total death (RR = 1.00, 95% CI 0.911.11)